MedTrace Logo

Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes

NCT06475105 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-10-22

No results posted yet for this study

Summary

Based on ADVOR trial, the potential of adding acetazolamide in increasing the success of decongestion, the amount of natriuresis and diuresis. However, the use of intravenous acetazolamide may not be possible in Indonesia, where the intravenous formulation is not available. This clinical research study is being conducted in single hospitals in Indonesia. We aim to learn if Oral Acetazolamide in addition to Furosemide intravenous works to treat congestion in Acute Decompensated Heart Failure, besides evaluating the total urinary output, change of NT pro BNP level, and safety profile of oral Acetazolamide.

The hypothesis of this study is oral acetazolamide works well to achieve successful decongestion.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

Oral Acetazolamide

Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days

DRUG

Placebo

Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days

Sponsors & Collaborators

  • Universitas Diponegoro

    lead OTHER

Principal Investigators

  • Ilham Uddin, MD · Department Cardiology and Vascular Medicine Universitas Diponegoro Kariadi General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-20
Primary Completion
2024-11-30
Completion
2024-12-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06475105 on ClinicalTrials.gov